Strategies for the inhibition of serine proteases

Cellular and Molecular Life Sciences

Volumn 58, Issue 4, 2001, Pages 596-624

  Walker, B ^a   Lynas, J F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Heterocyclic inhibitors; Inhibitor design; Peptide based inhibitors; Serine proteases; Synthetic inhibitors

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; BENZOXAZOLE DERIVATIVE; BETA LACTAM DERIVATIVE; BORONIC ACID DERIVATIVE; DYFLOS; ENZYME INHIBITOR; HETEROCYCLIC COMPOUND; ISOCOUMARIN DERIVATIVE; KETONE DERIVATIVE; METAL DERIVATIVE; PEPTIDE DERIVATIVE; SUCCINIMIDE DERIVATIVE; TOSYLLYSYL CHLOROMETHYL KETONE; TRIFLUOROMETHYLKETONE DERIVATIVE; UNCLASSIFIED DRUG;

DRUG DESIGN; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; NONHUMAN; REVIEW;

EID: 0035028658     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000884     Document Type: Review

References (247)

1. Plasminogen activators, tissue degradation and cancer
2. Urokinase-pype plasminogen activator and its receptor: New Targets for Anti-Metastatic Therapy
3. Transforming-growth factor beta-1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro
4. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer
5. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells
6. The urokinase plasminogen activator system in cancer metastasis
7. Chromogranin A: Processing proteinases in purified chromaffin granules: Contaminants or endogenous enzymes?
8. Killing of cytotoxic T-cells and natural killer cells: Multiple granule serine proteases as initiators of DNA fragmentation
9. Activation of the apoptotic protease CPP-32 by cytotoxic T-cell derived granzyme B
10. Tryptase: A mast cell serine protease
11. The roles of neutral proteases in asthma and rhinitis
12. Zymogen activation specificity and genomic structures of human neutrophil elastase and cathepsin G reveal a new branch of the chymotrypsinogen superfamily of serine proteases
13. Neutrophil elastase inhibitors as treatments for emphysema and chronic bronchitis
14. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes
15. The Coagulation cascade: Initiation, maintenance and regulation biochemistry
16. Fibrin-specific fibrinolysis
17. Genetics and deficiencies of the soluble regulatory proteins of the complement system
18. A new serine protease fold revealed by the crystal structure of human cytomegalovirus protease
19. The crystal structure of hepatitis C virus NS3 protease reveals a trypsin-like fold and a structural zinc binding site
20. Structural basis of substrate specificity in the serine proteases
21. Families and clans of serine peptidases
22. On the size of the active Site in proteases I. Papain
23. Natural protein proteinase inhibitors and their interaction with proteinases
24. Divining the serpin inhibition mechanism: A suicide substrate Springe
25. An atlas of serpin conformations
26. Low molecular weight enzyme inhibitors of microbial origin
27. New leupeptin analogues: Synthesis and inhibition data
28. Synthetic peptide-based inhibitors of the serine proteases
29. The synthesis of peptidylfluoromethanes and their properties as inhibitors of serine proteinases and cysteine proteinases
30. Synthesis of lysine-containing sulphonium salts and their properties as proteinase inhibitors
31. Inhibitors of serine proteases
32. α-diketone and α-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases
33. Peptide glyoxals: A novel class of inhibitor for serine and cysteine proteinases
34. Cysteine proteases and their inhibitors
35. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa
36. Thrombosis and coagulation
37. The preclinical and clinical pharmacology of novastan (argatroban): A small-molecule, direct thrombin inhibitor
38. Effects of napsagatran (Ro 46-6240), a new, synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: Comparison with an ex vivo annular perfusion chamber model
39. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor
40. Effects of melagatran, a new, low-molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
41. Inhibitors of tryptase for the treatment of mast cell-mediated diseases
42. Protease inhibitors: Current status and furore prospects
43. Stoichometric inhibition of chymotrypsin
44. Peptidic phosphorylating agents as irreversible inhibitors of serine proteases and models of the tetrahedral intermediate
45. Neutron diffraction identifies His 57 as the catalytic base in trypsin
46. Direct determination of the protonation states of aspartic acid-102 and histidine-57 in the tetrahedral intermediate of the serine proteases - Neutron structure of trypsin
47. Aminoalkylphosphonofluoridate derivatives - Rapid and potentially selective inactivators of the serine peptidases
48. Irreversible inhibition of serine proteases by peptide derivatives of (α-aminoalkyl) phosphonate diphenyl esters
49. Synthesis of new phosphonate inhibitors of serine proteases
50. Synthesis of phosphonopeptides as thrombin inhibitors
51. A convenient synthesis of N-protected diphenyl phosphonate ester analogues of ornithine, lysine and homolysine
52. Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases
53. Synthesis and kinetic studies of diphenyl 1-(N-peptidylamino) alkanephosphonate esters and their biotinylated derivatives as inhibitors of serine proteases and probes for lymphocyte granzymes
54. Synthesis and proteinase inhibitory activity of diphenyl phosphonate analogues of aspartic and glutamic acids
55. Inhibition of trypsin and thrombin by amino(4-amidinophenyl)methanephosphonate diphenyl ester derivatives: X-ray structures and molecular models
56. Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV
57. CD26 - A surface protease involved in T-cell activation
58. The tole of dipeptidyl peptidase IV in human T lymphocyte activation - Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro
59. Dipeptidyl peptidase IV in the immune system - Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes
60. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors
61. 2: A janus-faced proteinase with two opposite specificities
62. The application of a novel biotinylated probe for the characterisation of a latent proform of a cathepsin B-like proteinase produced by human breast cancer cells in culture
63. Synthesis, kinetic characterisation, and application of a biotinylated diazoketone for cathepsin B-like proteinases
64. The Synthesis, kinetic characterisation and application of biotinylated chloromethanes for the detection of chymotrypsin- and trypsin-like serine proteinases
65. Characterisation of the cysteine proteinases of the common liver fluke Fasciola hepatica using novel, active-site directed affinity labels
66. A novel trypsin-like enzyme in human breast cancer
67. The detection of serine elastase in human breast cancer
68. [l-(N-peptidylamino)alkyl] phosphonate esters - Synthesis and use in the inhibition and cellular localization of serine proteases
69. Identification and characterization of the cysteine and serine proteases of the trematode, Haplometra cylindricea and determination of their haemoglobinase activity
70. Synthesis and Kinetic Studies of Diphenyl 1-(N-Peptidylamino) Alkanephosphonate Esters and Their Biotinylated Derivatives as Inhibitors of Serine Proteases and Probes for Lymphocyte Granzymes
71. Peptidic phosphonylating agents as irreversible inhibitors of serine proteases and models of the tetrahedral intermediates
72. Crystal structures of α-lytic protease complexes with irreversibly bound phosphonate esters
73. The synthesis of phosphinic acid-based proteinase inhibitors. phosph.
74. Inhibition of serine proteases by peptidyl fluoromethyl ketones
75. Structure of chymotrypsin-trifluoromethyl ketone complexes - Comparison of slowly and rapidly equilibrating inhibitors
76. A versatile synthesis of peptidyl fluoromethyl ketones
77. Mechanism of slow-binding inhibition of human leukocyte elastase by trifluoromethyl ketones
78. X-ray diffraction analysis of the inhibition of porcine pancreatic elastase by a peptidyl trifluoromethylketone
79. Synthesis of peptidyl fluoromethyl ketones and peptidyl α-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase and rat and human neutrophil cathepsin G
80. Inhibition of human leukocyte elastase (HLE) by N-substituted peptidyl trifluoromethyl ketones
81. 1
82. Inhibition of human neutrophil elastase by ICI 200,355
83. Biologic characterization of ICI 280 880 and 200 355, novel inhibitors of human neutrophil elastase
84. Nonpeptidic inhibitors of human leukocyte elastase. 2. Design, synthesis and in vitro activity of a series of 3-amino-6-arylopyridin-2-one trifluoromethyl ketones
85. Inhibitors of human leukocyte elastase
86. Nonpeptidic inhibitors of human leukocyte elastase. 5. Design, synthesis and X-ray crystallography of a series of orally active 5-aminopyrimidin-6-one-containing trifluoromethyl ketones
87. Nonpeptidic inhibitors of human leukocyte elastase. 4. Design, synthesis and in vitro and in vivo of a series of β-carbolinone-containing trifluoromethyl ketones
88. Orally active, trifluoromethyl ketone inhibitors of human leukocyte elastase
89. Nonpeptidic inhibitors of human neutrophil elastase. 7. Design, synthesis, and in vitro activity of a series of pyridopyrimidine trifluoromethyl ketones
90. Synthesis and comparison of tripeptidylfluoroalkane thrombin inhibitors
91. Peptidomimetic inhibitors of the human cytomegalovirus protease
92. Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity and mechanism-based inhibitors
93. 3′
94. Inhibition of human leukocyte elastase (HLE) by N-substituted tripeptide trifluoromethyl ketones
95. Conversion of α-keto esters into β,β-difluoro-αketo esters and corresponding acids: A simple route to a novel class of serine protease inhibitors
96. G-Val-Pro-Val pentafluoroethyl ketones
97. Pharmacology of N-[4-(4-morpholinyl)benzoyl]-L-Valyl-N-[3,3,4,4,4-pentafluoro- 1(1-methylethyl)-2-oxobutyl]-L-prolinamide (MDL 101 146), a potent orally active inhibitor of human neutrophil elastase
98. 2-Phenylethane boronic acid - A possible transition state analog for chemotrypsin
99. Inhibition of subtilisin by boronic acids, potential analogues of tetrahedral reaction intermediates
100. X-ray crystallographic study of boronic acid adducts with subtilisin BPN' (Novo)
101. (R)-1-acetamido-2-phenylethaneboronic acid - A specific transition state analogue for chymotrypsin
102. Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G and chymotrypsin by peptide boronic acids
103. Serine protease mechanism - Structure of an inhibitory complex of alpha-lytic protease and a tightly bound peptide boronic acid
104. Kinetic properties of the binding of alpha-lytic protease to peptide boronic acids
105. X-ray diffraction analysis of the inhibition of porcine pancreatic elastase by a peptidyl trifluoromethylketone
106. N-15 NMR-spectroscopy of the catalytic triad histidine of a serine protease in peptide boronic acid inhibitor complexes
107. Observation of tightly bound B-11 nuclear magnetic resonance signals of serine proteases - Direct solution evidence for tetrahedral geometry around the boron in the putative transition state analogues
108. Identification of serine and histidine adducts in the complexes of trypsin and trypsinogen with peptide and non-peptide boronic acid inhibitors by 1H-NMR spectroscopy
109. NMR-studies of the alphachymotrypsin-(R)-1-acetamido-2-(4-fluorophenyl)ethane-1-boronic acid complex
110. Biochemical and crystallographic characterization of homologous non-peptidic thrombin inhibitors having alternate binding
111. Design and synthesis of ring-constrained boropeptide thrombin inhibitors
112. S-1 Heterocyclic thrombin inhibitors
113. The selective inhibition of thrombin by peptides of boroarginine
114. Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-BoroArg-OH and its lysine, amidine, homolysine and ornithine analogues
115. The solution conformation of (D)Phe-Pro-Containing Peptides - Implications on the Activity of Ac-(D)Phe-Pro-BoroArg-OH, a potent thrombin inhibitor
116. The Refined 1.9 angstrom X-ray crystal structure of D-Phe-Pro-Arg chloromethyl ketone-inhibited human alpha-thrombin - Structure analysis, overall structure, electrostatic properties, detailed active site geometry and structure-function relationships
117. Design and synthesis of ring-constrained boropeptide thrombin inhibitors
118. Synthesis and activity studies of novel boropeptide thrombin inhibitors
119. 2 analogues of DuP 714 with greater selectivity over complement factor I and an improved safety profile
120. In vivo characterization of a new, synthetic thrombin inhibitor
121. Acute toxicity of synthetic thrombin inhibitors caused by inhibition of complement factor I
122. Synthetic low molecular weight thrombin inhibitors - Molecular design and pharmacological profile
123. 1 position
124. 1 side chains as highly selective inhibitors of thrombin
125. 1 binding site replaces binding of a basic side chain
126. Inhibition of dipeptidyl amino-peptidase IV (DP-IV) by Xaa-BoroPro dipeptides and use of these inhibitors to examine the role of Dp-IV in T-cell function
127. Separation of L-Pro-DL-BoroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase 4. A new method for the analysis of slow, tight-binding inhibition
128. The efficient synthesis and simple resolution of a prolineboronate ester suitable for enzyme inhibition studies
129. Studies on proline boronic acid dipeptide inhibitors of dipeptidyl peptidase IV - Identification of a cyclic species containing a B-N bond
130. 2 position of Xaa-BoroPro dipeptides
131. Mechanism of proline-specific proteinases. 1. Substrate-specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium menigosepticum
132. Inhibition of IgA1 proteinases from Neisseria gonorrhoeae and Haemophilius influenzae by peptidyl prolyl boronic acids
133. i ∼ nanomolar inhibitors of serine proteases selected by binding or chemistry on an enzyme surface
134. Potentially macrocyclic peptidyl boronic acids as chymotrypsin inhibitors
135. Trypsin substrates derived from benzamidine: Application to active site titration and isolation of acyl enzyme intermediates
136. Studies with inverse substrates - Inhibitors of trypsin-like serine proteases
137. Inverse substrates for trypsin and trypsin-like enzymes
138. Inverse substrates 13. Analysis of latent properties of trypsin-acyl trypsins derived from enantiomeric pairs of inverse substrates
139. Inverse substrates 11. A novel chiral microenvironmental probe at the active site of trypsin - Extrinsic cotton effects of acyl-trypsin and an enantiomeric pair of chromophores
140. Inverse substrates 16. Comparative studies on the structure of active sites - Behaviour of inverse substrates toward trypsin and related enzymes
141. Fibrinolysis with acyl-enzymes - A mew approach to thrombolytic therapy
142. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis
143. The thrombolytic activities in a rabbit model of venous thrombosis of an acyl human plasmin derivative (BRL 26920) and an acyl-streptokinase human plasminogen activator complex (BRL 26921)
144. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus
145. Inverse substrates 14. Behaviour of trypsin and related enzymes toward amidinophenyl esters
146. Peptidyl inverse esters of p-methoxybenzoic acid: A novel class of potent inactivator of the serine proteases
147. Peptide argininol inverse substrates of anisic acid: Novel inhibitors of the trypsin-like serine proteases bioorg
148. Design, synthesis and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl α-ketobenzoxazoles, and the X-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole
149. Peptidyl α-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency
150. Peptidyl α-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl α-ketobenzoxazoles
151. Enzyme inhibitors - Ground state transition state analogues
152. α-keto thiazole inhibitors of prolyl endopeptidase
153. Synthesis and structure-activity relationships of peptidyl α-keto heterocycles as novel inhibitors of prolyl endopeptidase
154. Peptide α-keto thiazole as potent thrombin inhibitors
155. 1-argininoyl heterocycles
156. 1′, subsite: Tripeptide transition state analogues based on a heterocycle-activated carbonyl group
157. Antibiotics and other related microbial products
158. Inhibition studies of some serine and cysteine proteinases by new leupeptin analogues
159. Bioactive marine metabolites 33. Cyclotheonamides, potent thrombin inhibitors, from a marine sponge, Theonella spp.
160. Molecular basis for the inhibition of human alpha-thrombin by the macrocyclic peptide cyclotheonamide A
161. Inhibition of thrombin and other trypsin-like serine proteases by cyclotheonamide A
162. Three more cyclotheonamides, C, D and E, potent thrombin inhibitors from the marine sponge Theonella swinhoei
163. Cyclotheonamide derivatives: Synthesis and thrombin inhibition. Exploration of specific structure-function issues
164. Total synthesis of cyclotheonamide B, a facile route towards analogues
165. A90720A, A serine protease inhibitor isolated from a terrestrial blue-green alga, Microchaete loktakensis
166. Aeruginosins 102-A and B, new thrombin inhibitors from the cyanobacterium Microcystis viridis (NIES-102)
167. Aeruginosin 298A, a thrombin and trypsin inhibitor from the blue-green alga Microcystis aeruginosia (NIES-298)
168. Aeruginosin-98A and aeruginosin-98B, trypsin inhibitors from the blue-green alga Microcystis aeruginosa (NIES-98)
169. Structure of thrombin inhibited by aeruginosin 298-A from a blue-green algae
170. Use of peptide aldehydes to generate transition state analogues of elastase
171. Atomic structure of the trypsin-aeruginosin 98-B complex
172. Serine protease selectivity of the thrombin inhibitor D-Phe-Pro-agmatine and its homologs
173. Determination of the absolute configuration and total synthesis of radiosumin, a trypsin inhibitor from a freshwater blue-green alga
174. Irreversible inhibition of porcine pancreatic elastase by amino acid-derived imidazole N-carboxamides
175. The irreversible inhibition of urokinase, kidney cell plasminogen activator, plasmin and trypsin by 1 -(amino-n-hexyl)-carbamoyl imidazole
176. The lossen rearrangement in biological systems - Inactivation of leukocyte elastase and alpha-chymotrypsin by (dl)-3-benzyl-N-(methanesulfonyloxy) Succinimide
177. Inhibition of human leukocyte elastase by derivatives of N-hydroxysuccinimide. A structure-activity-relationship study
178. Catalysis by human leukocyte elastase 4. Role of secondary subsite interactions
179. Catalysis by human leukocyte elastase - Aminolysis of acyl enzymes by amino acid amides and peptides
180. 1 subsites of porcine pancreatic elastases
181. Ionic inhibitors of human leukocyte elastase: Pyridinium and phenyl carboxylate derivatives of 3alkyl-N-hydroxysuccinimide
182. Reactivity of human leukocyte elastase and porcine pancreatic elastase toward peptide 4-nitroanilides containing model desmosine residues - Evidence that human leukocyte elastase is selective for crosslinked regions of elastase
183. Inhibitors of leukocyte proteinase 3
184. 31P NMR nuclear magnetic resonance spectroscopy
185. Inhibitors of human neutrophil cathepsin G: Structural and biochemical studies
186. Enantioselective inhibition of human leukocyte elastase
187. 3-(Alkylthio)-N-hydroxysuccinimide derivatives: Potent inhibitors of human leukocyte elastase
188. Design, synthesis and biological evaluation of succinimide derivatives as potential mechanism-based inhibitors of human leukocyte elastase, cathepsin G and proteinase 3
189. Oxidation of methionyl residues in proteins tools, targets and reversal
190. Dual inhibition of human leukocyte elastase and lipid peroxidation: In nitro and in vivo activities of azabicyclo [2,2,2]octane and perhydroindole derivatives
191. Novel potential mechanism-based inhibitors of human leukocyte elastase and cathepsin G: Derivatives of isothiazolidin-3-one
192. Orally bioavailable benzisothiazolone inhibitors of human leukocyte elastase
193. The design of potent and stable benzisothiazolone inhibitors of human leukocyte elastase
194. A novel cass of cyclic β-dicarbonyl leaving groups and their use in the design of benzoisothiazolone human leukocyte elastase inhibitors
195. Reaction of serine proteases with substituted isocoumarins - Discovery of 3,4-dichloroisocoumarin, a new general mechanism serine protease inhibitor
196. 3, 4-dichloroisocoumarin inhibits the thiol protease calpain
197. 14C]-3, 4-dichloroisocoumarin with subunits of pituitary and spleen multicatalytic proteinase complexes (proteasomes)
198. Isocoumarin inhibitors of serine peptidases
199. Stereospecific reaction of 3-methoxy-4-chloro-7-aminoisocoumatin with crystalline porcine pancreatic elastase
200. Enzyme-inhibition studies as aided by interactive computer graphics and X-ray crystallography
201. Structural study of porcine pancreatic elastase complexed with 7-amino-3-(2-bromoethoxy)-4-chloroisocoumafin as a nonreactivatable doubly covalent enzyme-inhibitor complex
202. Effect of the 7-amino substituent on the inhibitory potency of mechanism-based isocoumarin inhibitors for porcine pancreatic and human neutrophil elastases - A 1.85 angstrom X-ray structure of the complex between porcine pancreatic elastase and 7-[(N-tosylphenylalanyl)amino]-4-chloro-3-methoxyisocoumarin
203. The 2.2 Angstrom resolution X-ray crystal structure of the complex of trypsin inhibited by 4-chloro-3-ethoxy-7-guanidinoisocoumarin - A proposed model of the thrombin-inhibitor complex
204. Thioester chromogenic substrates for human factor VIIa - Substituted isocoumarins are inhibitors of factor VIIa and in vitro anticoagulants
205. Mechanism-based isocoumarin inhibitors for blood coagulation serine proteases - Effect of the 7-substituent in 7-amino-4-chloro-3-(isothioureidoalkoxy) isocoumarins on inhibitory and anticoagulant potency
206. Substituted isocoumarins as inhibitors of complement serine proteases
207. Human and murine cytotoxic T-lymphocyte serine proteases - Subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins
208. The function of lymphocyte proteases - Inhibition and restoration of granule-mediated lysis with isocoumarin serine protease inhibitors
209. Determination of activatable proacrosin/acrosin in bovine sperm using an irreversible isocoumarin serine protease inhibitor
210. Biotinylated isocoumarins, new inhibitors and reagents for detection, localization and isolation of serine proteases
211. Characterization, application and potential uses of biotin-tagged inhibitors for lymphocyte serine proteases (granzymes)
212. Molecular mechanics studies on non-classical beta lactam structures
213. Beta lactamases
214. Beta lactamase inhibitors
215. Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase
216. Crystallographic study of a β-lactam inhibitor complex with elastase at 1.84 Å resolution
217. Mechanism of inhibition of human PMN-elastase by monocyclic beta-lactams
218. An investigation into the mechanism of elastase inhibition by cephalosporins using electrospray ionization mass spectrometry
219. Mechanism of inhibition of human leukocyte elastase by two cephalosporin derivatives
220. Electrospray ionization mass spectrometry as a mechanistic tool: Mass of human leukocyte elastase and a β-lactam-derived E-I complex
221. Mechanism of inhibition of human leukocyte elastase by monocyclic β-lactams
222. Mechanism of inhibition of human leukocyte elastase by beta-lactams 3. Use of electrospray ionization mass spectrometry and 2-dimensional NMR techniques to identify beta-lactam-derived E-I complexes
223. Mechanism of inhibition of human leukocyte elastase by beta lactams 2. Stability, reactivation kinetics and prodcuts of beta-lactam-derived E-I complexes
224. Monocyclic β-lactam inhibitors of human leukocyte elastase
225. Inhibition of human leukocyte elastase (HLE) by novel bicyclic β-lactams
226. Inhibition of human leukocyte elastase 1. Inhibition by C-7 substituted cephalosporin tert-butyl esters
227. Inhibition of human leukocyte elastase 2. Inhibition by substituted cephalosporin esters and amides
228. Synthesis and evaluation of new elastase inhibitors I. 1,1-dioxocephem-4-thiolesters
229. Studies on cephem sulphones as mechanism-based inactivators of uman leukocyte elastase III. Reactions ensuing from chemical β-lactam cleavage
230. Synthesis of 7α-methoxy-2-(1,3-dithiolan-2-ylidene)cephem sulphones. A new series of human leukocyte elastase inhibitors
231. 7-alkylidenecephalosporin esters as inhibitors of human leukocyte elastase
232. Inhibition of human leukocyte elastase 5. Inhibition by 6-alkyl substituted penem benzyl esters
233. Inhibition of human leukocyte elastase 6. Inhibition by 6-substituted penicillin esters
234. Inhibition of human leukocyte elastase 7. Inhibition by 6-substituted penicillin amides
235. Prostate specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
236. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease
237. Design and Synthesis of Novel Monocyclic β-Lactam Inhibitors of Prostate Specific Antigen
238. Design and synthesis of monocyclic β-lactams as mechanism-based inhibitors of human cytomegalovirus protease
239. Solution-phase synthesis of a combinatorial monocyclic β-lactam library: Potential protease inhibitors
240. Beta-lactams as thrombin inhibitors
241. Azetidin-2-one derivatives as inhibitors of thrombin bioorg
242. Design of potent, selective zinc-mediated serine protease inhibitors
243. 2+ to mediate potent, specific inhibition of serine proteases
244. A novel approach to serine protease inhibition: Kinetic characterization of inhibitors whose potencies and selectivities are dramatically enhanced by zinc (II)